vs
Side-by-side financial comparison of Dingdong (Cayman) Ltd (DDL) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
Dingdong (Cayman) Ltd is the larger business by last-quarter revenue ($115.3M vs $60.1M, roughly 1.9× RHYTHM PHARMACEUTICALS, INC.). Dingdong (Cayman) Ltd runs the higher net margin — 5.8% vs -92.6%, a 98.4% gap on every dollar of revenue.
Dingdong (Cayman) Ltd operates a leading on-demand grocery e-commerce platform primarily serving the Chinese market. It provides fresh produce, daily necessities, ready-to-eat meals, and household staples to urban consumers, leveraging optimized supply chains and localized logistics networks to offer fast, reliable 30-minute delivery services, prioritizing product freshness and user convenience.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
DDL vs RYTM — Head-to-Head
Income Statement — Q3 FY2022 vs Q1 FY2026
| Metric | ||
|---|---|---|
| Revenue | $115.3M | $60.1M |
| Net Profit | $6.7M | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | 5.3% | -87.1% |
| Net Margin | 5.8% | -92.6% |
| Revenue YoY | — | 83.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.02 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | — | $57.3M | ||
| Q3 25 | — | $51.3M | ||
| Q2 25 | — | $48.5M | ||
| Q1 25 | — | $32.7M | ||
| Q4 24 | — | $41.8M | ||
| Q3 24 | — | $33.3M | ||
| Q2 24 | — | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | — | $-52.9M | ||
| Q2 25 | — | $-46.6M | ||
| Q1 25 | — | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | — | $-43.6M | ||
| Q2 24 | — | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | — | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | — | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | — | -103.1% | ||
| Q2 25 | — | -96.1% | ||
| Q1 25 | — | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | — | -131.2% | ||
| Q2 24 | — | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | — | $-0.73 | ||
| Q3 25 | — | $-0.82 | ||
| Q2 25 | — | $-0.75 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | — | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $113.7M | $340.6M |
| Total DebtLower is stronger | $135.8K | — |
| Stockholders' EquityBook value | $4.5M | $122.9M |
| Total Assets | $178.3M | $442.3M |
| Debt / EquityLower = less leverage | 0.03× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M |
| Q1 26 | — | $122.9M | ||
| Q4 25 | — | $139.1M | ||
| Q3 25 | — | $148.8M | ||
| Q2 25 | — | $-11.9M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | — | $21.7M | ||
| Q3 24 | — | $11.2M | ||
| Q2 24 | — | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | — | $480.2M | ||
| Q3 25 | — | $506.9M | ||
| Q2 25 | — | $372.7M | ||
| Q1 25 | — | $386.7M | ||
| Q4 24 | — | $392.3M | ||
| Q3 24 | — | $363.6M | ||
| Q2 24 | — | $381.8M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.